FDA Warns of New Blood Cancers With Sarcoma, Lymphoma Drug

(MedPage Today) -- The FDA on Monday alerted clinicians about the risk of new primary hematologic malignancies in patients treated with tazemetostat (Tazverik), a sarcoma and lymphoma drug now being pulled from global markets. The risk was known...
Source
MedPage Today
Opens original article in a new tab



